Pharmacological management of heart failure in adults with congenital heart disease.
ACEI/ARBs
ARNIs
Beta blockers
Congenital heart disease
Heart failure
MRAs
SGLT-2 inhibitors
Journal
Heart failure reviews
ISSN: 1573-7322
Titre abrégé: Heart Fail Rev
Pays: United States
ID NLM: 9612481
Informations de publication
Date de publication:
12 Aug 2024
12 Aug 2024
Historique:
accepted:
25
07
2024
medline:
13
8
2024
pubmed:
13
8
2024
entrez:
12
8
2024
Statut:
aheadofprint
Résumé
Congenital heart disease (CHD) is the most common global congenital defect affecting over 2.4 million individuals in the United States. Ongoing medical and surgical advancements have improved the survival of children with CHD leading to a shift where, as of 2010, adults constitute two-thirds of the CHD patient population. The increasing number and aging of adult congenital heart disease (ACHD) patients present a clinical challenge due to heightened complexity, morbidity, and mortality. Studies indicate that 1 in 13 ACHD patients will develop heart failure (HF) in their lifetime. ACHD-HF patients experience more frequent emergency department visits, higher hospitalization rates, longer hospital stays, and higher mortality compared to non-ACHD patients with heart failure (non-ACHD-HF). Despite HF being the leading cause of death in ACHD patients, there is a notable gap in evidence regarding treatment. While guideline-directed medical therapy (GDMT) has been extensively studied in non-ACHD-HF, research specific to ACHD-HF individuals is limited. This article aims to comprehensively review available literature addressing the pharmacological treatment of ACHD-HF.
Identifiants
pubmed: 39134780
doi: 10.1007/s10741-024-10428-4
pii: 10.1007/s10741-024-10428-4
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
CDC. Data and statistics on congenital heart defects | CDC. Centers for Disease Control and Prevention. Published September 19, 2023. Accessed October 6, 2023. https://www.cdc.gov/ncbddd/heartdefects/data.html
Congenital disorders. Accessed October 6, 2023. https://www.who.int/news-room/fact-sheets/detail/birth-defects
Gilboa SM, Devine OJ, Kucik JE et al (2016) Congenital heart defects in the United States: estimating the magnitude of the affected population in 2010. Circulation 134(2):101–109. https://doi.org/10.1161/CIRCULATIONAHA.115.019307
doi: 10.1161/CIRCULATIONAHA.115.019307
pubmed: 27382105
Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M (2014) Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation 130(9):749–756. https://doi.org/10.1161/CIRCULATIONAHA.113.008396
doi: 10.1161/CIRCULATIONAHA.113.008396
pubmed: 24944314
Mandalenakis Z, Giang KW, Eriksson P et al (2020) Survival in children with congenital heart disease: have we reached a peak at 97%? J Am Heart Assoc Cardiovasc Cerebrovasc Dis 9(22):e017704. https://doi.org/10.1161/JAHA.120.017704
doi: 10.1161/JAHA.120.017704
Wu M, Lu C, Chen H, Kao F, Huang S (2018) Adult congenital heart disease in a nationwide population 2000–2014: epidemiological trends, arrhythmia, and standardized mortality ratio. J Am Heart Assoc 7(4):e007907. https://doi.org/10.1161/JAHA.117.007907
doi: 10.1161/JAHA.117.007907
pubmed: 29437602
Tutarel O, Kempny A, Alonso-Gonzalez R et al (2014) Congenital heart disease beyond the age of 60: emergence of a new population with high resource utilization, high morbidity, and high mortality. Eur Heart J 35(11):725–732. https://doi.org/10.1093/eurheartj/eht257
doi: 10.1093/eurheartj/eht257
pubmed: 23882067
Dellborg M, Giang KW, Eriksson P et al (2023) Adults with congenital heart disease: trends in event-free survival past middle age. Circulation 147(12):930–938. https://doi.org/10.1161/CIRCULATIONAHA.122.060834
doi: 10.1161/CIRCULATIONAHA.122.060834
pubmed: 36571845
Gurvitz M, Dunn JE, Bhatt A et al (2020) Characteristics of adults with congenital heart defects in the United States. J Am Coll Cardiol 76(2):175–182. https://doi.org/10.1016/j.jacc.2020.05.025
doi: 10.1016/j.jacc.2020.05.025
pubmed: 32646567
Bergh N, Skoglund K, Fedchenko M et al (2023) Risk of heart failure in congenital heart disease: a nationwide register-based cohort study. Circulation 147(12):982–984. https://doi.org/10.1161/CIRCULATIONAHA.122.061546
doi: 10.1161/CIRCULATIONAHA.122.061546
pubmed: 36533451
Mandalenakis Z, Rosengren A, Lappas G et al (2018) Atrial fibrillation burden in young patients with congenital heart disease. Circulation 137(9):928–937. https://doi.org/10.1161/CIRCULATIONAHA.117.029590
doi: 10.1161/CIRCULATIONAHA.117.029590
pubmed: 29092907
Fedchenko M, Mandalenakis Z, Giang KW, Rosengren A, Eriksson P, Dellborg M (2020) Long-term outcomes after myocardial infarction in middle-aged and older patients with congenital heart disease—a nationwide study. Eur Heart J 42(26):2577–2586. https://doi.org/10.1093/eurheartj/ehaa874
doi: 10.1093/eurheartj/ehaa874
Burstein DS, Rossano JW, Griffis H et al (2021) Greater admissions, mortality and cost of heart failure in adults with congenital heart disease. Heart 107(10):807–813. https://doi.org/10.1136/heartjnl-2020-318246
doi: 10.1136/heartjnl-2020-318246
pubmed: 33361349
Zomer AC, Vaartjes I, van der Velde ET et al (2013) Heart failure admissions in adults with congenital heart disease; risk factors and prognosis. Int J Cardiol 168(3):2487–2493. https://doi.org/10.1016/j.ijcard.2013.03.003
doi: 10.1016/j.ijcard.2013.03.003
pubmed: 23602867
Engelings CC, Helm PC, Abdul-Khaliq H et al (2016) Cause of death in adults with congenital heart disease - an analysis of the German National Register for Congenital Heart Defects. Int J Cardiol 211:31–36. https://doi.org/10.1016/j.ijcard.2016.02.133
doi: 10.1016/j.ijcard.2016.02.133
pubmed: 26970963
Verheugt CL, Uiterwaal CSPM, van der Velde ET et al (2010) Mortality in adult congenital heart disease. Eur Heart J 31(10):1220–1229. https://doi.org/10.1093/eurheartj/ehq032
doi: 10.1093/eurheartj/ehq032
pubmed: 20207625
Zengin E, Sinning C, Blaum C et al (2021) Heart failure in adults with congenital heart disease: a narrative review. Cardiovasc Diagn Ther 11(2):529–537. https://doi.org/10.21037/cdt-20-632
doi: 10.21037/cdt-20-632
pubmed: 33968631
Diller GP, Kempny A, Alonso-Gonzalez R et al (2015) Survival prospects and circumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre. Circulation 132(22):2118–2125. https://doi.org/10.1161/CIRCULATIONAHA.115.017202
doi: 10.1161/CIRCULATIONAHA.115.017202
pubmed: 26369353
Sabanayagam A, Cavus O, Williams J, Bradley E (2018) Management of heart failure in adult congenital heart disease. Heart Fail Clin 14(4):569–577. https://doi.org/10.1016/j.hfc.2018.06.005
doi: 10.1016/j.hfc.2018.06.005
pubmed: 30266365
Kouatli AA, Garcia JA, Zellers TM, Weinstein EM, Mahony L (1997) Enalapril does not enhance exercise capacity in patients after Fontan procedure. Circulation 96(5):1507–1512. https://doi.org/10.1161/01.cir.96.5.1507
doi: 10.1161/01.cir.96.5.1507
pubmed: 9315539
Hechter SJ, Fredriksen PM, Liu P, Veldtman G, Merchant N, Freeman M, Therrien J, Benson L, Siu S, Webb G (2001) Angiotensin-converting enzyme inhibitors in adults after the Mustard procedure. Am J Cardiol 87(5):660–3, A11. https://doi.org/10.1016/s0002-9149(00)01452-1
doi: 10.1016/s0002-9149(00)01452-1
pubmed: 11230861
Lester SJ, McElhinney DB, Viloria E, Reddy GP, Ryan E, Tworetzky W, Schiller NB, Foster E (2001) Effects of losartan in patients with a systemically functioning morphologic right ventricle after atrial repair of transposition of the great arteries. Am J Cardiol 88(11):1314–1316. https://doi.org/10.1016/s0002-9149(01)02098-7
doi: 10.1016/s0002-9149(01)02098-7
pubmed: 11728365
Zaragoza-Macias E, Zaidi AN, Dendukuri N, Marelli A (2019) Medical therapy for systemic right ventricles: a systematic review (Part 1) for the 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 73(12):1564–1578. https://doi.org/10.1016/j.jacc.2018.08.1030
doi: 10.1016/j.jacc.2018.08.1030
pubmed: 30121238
Doughan ARK, McConnell ME, Book WM (2007) Effect of beta blockers (carvedilol or metoprolol XL) in patients with transposition of great arteries and dysfunction of the systemic right ventricle. Am J Cardiol 99:704–706
doi: 10.1016/j.amjcard.2006.10.025
pubmed: 17317376
Bouallal R, Godart F, Francart C, Richard A, Foucher-Hossein C, Lions C (2010) Interest of β-blockers in patients with right ventricular systemic dysfunction. Cardiol Young 20(6):615–619. https://doi.org/10.1017/S1047951110000764
doi: 10.1017/S1047951110000764
pubmed: 20519056
Josephson CB, Howlett JG, Jackson SD, Finley J, Kells CM (2006) A case series of systemic right ventricular dysfunction post atrial switch for simple D-transposition of the great arteries: the impact of beta-blockade. Can J Cardiol 22(9):769–772. https://doi.org/10.1016/s0828-282x(06)70293-8
doi: 10.1016/s0828-282x(06)70293-8
pubmed: 16835671
Giardini A, Lovato L, Donti A, Formigari R, Gargiulo G, Picchio FM, Fattori R (2007) A pilot study on the effects of carvedilol on right ventricular remodelling and exercise tolerance in patients with systemic right ventricle. Int J Cardiol 114(2):241–246. https://doi.org/10.1016/j.ijcard.2006.01.048
doi: 10.1016/j.ijcard.2006.01.048
pubmed: 21882492
Maurer SJ, Pujol Salvador C, Schiele S, Hager A, Ewert P, Tutarel O (2020) Sacubitril/valsartan for heart failure in adults with complex congenital heart disease. Int J Cardiol 300:137–140. https://doi.org/10.1016/j.ijcard.2019.06.031
doi: 10.1016/j.ijcard.2019.06.031
pubmed: 31242968
Yan L, Loh JK, Le Tan J (2021) Sacubitril/valsartan for heart failure in patients with complex adult congenital heart disease – Experience from a tertiary centre in Singapore. International Journal of Cardiology Congenital Heart Disease 6:100268. https://doi.org/10.1016/j.ijcchd.2021.100268
doi: 10.1016/j.ijcchd.2021.100268
Zandstra TE, Nederend M, Jongbloed MRM et al (2021) Sacubitril/valsartan in the treatment of systemic right ventricular failure. Heart 107(21):1725–1730. https://doi.org/10.1136/heartjnl-2020-318074
doi: 10.1136/heartjnl-2020-318074
pubmed: 33452121
Fusco F, Scognamiglio G, Merola A et al (2023) Safety and efficacy of sacubitril/valsartan in patients with a failing systemic right ventricle: a prospective single-center study. Circ Heart Fail 16(2):e009848. https://doi.org/10.1161/CIRCHEARTFAILURE.122.009848
doi: 10.1161/CIRCHEARTFAILURE.122.009848
pubmed: 36458541
Egorova AD, Nederend M, Tops LF, Vliegen HW, Jongbloed MRM, Kiès P (2022) The first experience with sodium-glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure. ESC Heart Fail 9(3):2007–2012. https://doi.org/10.1002/ehf2.13871
doi: 10.1002/ehf2.13871
pubmed: 35355435
Muneuchi J, Sugitani Y, Kobayashi M, Ezaki H, Yamada H, Watanabe M (2022) Feasibility and safety of sodium glucose cotransporter-2 inhibitors in adults with heart failure after the fontan procedure. Case Rep Cardiol 2022:5243594. https://doi.org/10.1155/2022/5243594 . (Published 2022 Dec 9)
doi: 10.1155/2022/5243594
pubmed: 36530388
Saef J, Sundaravel S, Ortega-Legaspi J, Vaikunth S (2023) Safety and treatment experience with sodium/glucose cotransporter-2 inhibitors in adult patients with congenital heart disease. J Card Fail 29(6):974–975. https://doi.org/10.1016/j.cardfail.2023.03.011
doi: 10.1016/j.cardfail.2023.03.011
pubmed: 37004868
Neijenhuis RML, Nederend M, Jongbloed MRM et al (2023) The potential of sodium-glucose cotransporter 2 inhibitors for the treatment of systemic right ventricular failure in adults with congenital heart disease. Front Cardiovasc Med 10:1093201. https://doi.org/10.3389/fcvm.2023.1093201 . (Published 2023 Jun 26)
doi: 10.3389/fcvm.2023.1093201
pubmed: 37435053
Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM, Crumb SR, Dearani JA, Fuller S, Gurvitz M, Khairy P, Landzberg MJ, Saidi A, Valente AM, Van Hare GF (2019) 2018 AHA/ACC Guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139(14):e698–e800. https://doi.org/10.1161/CIR.0000000000000603 . (Erratum.In:Circulation.2019Apr2;139(14):e833-e834)
doi: 10.1161/CIR.0000000000000603
pubmed: 30586767
Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GP, Lung B, Kluin J, Lang IM, Meijboom F, Moons P, Mulder BJM, Oechslin E, Roos-Hesselink JW, Schwerzmann M, Sondergaard L, Zeppenfeld K (2021) ESC Scientific Document Group. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J 42(6):563–645. https://doi.org/10.1093/eurheartj/ehaa554
doi: 10.1093/eurheartj/ehaa554
pubmed: 32860028
Iacobazzi D, Alvino VV, Caputo M, Madeddu P (2022) Accelerated cardiac aging in patients with congenital heart disease. Front Cardiovasc Med 26(9):892861. https://doi.org/10.3389/fcvm.2022.892861 . (Erratum.In:FrontCardiovascMed.2022Dec15;9:1112510)
doi: 10.3389/fcvm.2022.892861
CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316(23):1429–35. https://doi.org/10.1056/NEJM198706043162301
doi: 10.1056/NEJM198706043162301
Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325(5):293–302. https://doi.org/10.1056/NEJM199108013250501
doi: 10.1056/NEJM199108013250501
pubmed: 2057034
Spath NB, Gomez M, Everett RJ, Semple S, Chin CWL, White AC, Japp AG, Newby DE, Dweck MR (2019) Global longitudinal strain analysis using cardiac MRI in aortic stenosis: comparison with left ventricular remodeling, myocardial fibrosis, and 2-year clinical outcomes. Radiol Cardiothorac Imaging 1(4):e190027. https://doi.org/10.1148/ryct.2019190027
doi: 10.1148/ryct.2019190027
pubmed: 33778518
Molnár AÁ, Sánta A, Merkely B (2023) Echocardiography imaging of the right ventricle: focus on three-dimensional echocardiography. Diagnostics 13(15):2470. https://doi.org/10.3390/diagnostics13152470
doi: 10.3390/diagnostics13152470
pubmed: 37568832
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F, EMPEROR-Reduced Trial Investigators (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413–1424. https://doi.org/10.1056/NEJMoa2022190
doi: 10.1056/NEJMoa2022190
pubmed: 32865377
Westhoff-Bleck M, Podewski E, Tutarel O, Wenzel D, CappelloCBertram H et al (2013) Prognostic value of NT-proBNP in patients with systemic morphological right ventricles: a single-centre experience. Int J Cardiol 169(6):433–8. https://doi.org/10.1016/j.ijcard.2013.10.014
doi: 10.1016/j.ijcard.2013.10.014
pubmed: 24169536
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM, DAPA-HF Trial Committees and Investigators (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995–2008. https://doi.org/10.1056/NEJMoa1911303
doi: 10.1056/NEJMoa1911303
pubmed: 31535829